The State of Life Sciences Workforce Health 2027
How pharma, biotech and life-sciences manufacturers actually run lab clearance, OEL-band surveillance, HPAPI and hazardous-drug programs, vivarium health, respirator clearance and immunizations — and where fragmentation between R&D campuses, GMP sites, providers and the medical record quietly costs the most.
Four findings from this year's benchmark
The median life-sciences enterprise runs worker clearance across R&D campuses, vivaria, pilot plants and manufacturing sites that do not share a medical record.
OEL-band and respirator clearances are frequently re-run because no system shows who is already current for the compound, potency band and site.
Vivarium and HPAPI surveillance are where quiet lapses hurt most — questionnaires, biomonitoring and follow-up sit in separate local queues.
Organizations on one structured occupational-health record cut clearance-cycle and audit-prep time dramatically.
Illustrative findings for this concept site — representative figures, not a published dataset.
Get the report
Download the full benchmark — findings, methodology and the 12-month consolidation roadmap. We'll email you the PDF.
- Executive summary & methodology
- The seven life-sciences workforces, benchmarked
- Compound, OEL-band & respirator clearance benchmarks
- HPAPI, hazardous-drug and vivarium surveillance
- The true cost of site-by-site workforce health
- A 12-month consolidation roadmap
Prefer to explore first? See the Pharma & Life Sciences workforce health hub →